nach oben

Erschienen in:

23.08.2019 | Szintigrafie | Positionspapiere

Diagnostik und Therapie der kardialen Amyloidose

Positionspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK)

verfasst von: Univ.-Prof. Dr. med. A. Yilmaz, Univ.-Prof. Dr. med. J. Bauersachs, PD Dr. med. I. Kindermann, Prof. Dr. med. K. Klingel, Prof. Dr. med. F. Knebel, Prof. Dr. med. B. Meder, Dr. med. C. Morbach, Univ.-Prof. Dr. med. E. Nagel, Univ.-Prof. Dr. med. E. Schulze-Bahr, Dr. med. F. aus dem Siepen, Univ.-Prof. Dr. med. N. Frey

Erschienen in: Die Kardiologie | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Systemische Amyloidoseformen, die das Herz betreffen, sind v. a. die Leichtketten(AL)- und die ATTR-Amyloidosen, bei der es zur Ablagerung von fehlgefaltetem Transthyretin kommt (entweder als Wildtyp [wtATTR]-Form oder mutiert [mATTR]). Neben speziellen kardialen Biomarkern stehen heutzutage moderne nichtinvasive Bildgebungsverfahren wie das Herz-MRT oder szintigraphische Verfahren zur Verfügung, die die konventionelle Echokardiographie ergänzen und neben der Diagnose einer kardialen Amyloidose auch noch eine exakte Erfassung des Ausprägungsgrades ermöglichen. Als invasives diagnostisches Verfahren spielt die Endomyokardbiopsie weiterhin eine zentrale Rolle für die histopathologische Verifizierung bzw. Subtypisierung der kardialen Amyloidose. Wesentliches Ziel des in diesem Positionspapier skizzierten Diagnosepfades ist es, das Vorliegen einer kardialen Amyloidose möglichst sicher und frühzeitig zu erfassen, das Ausmaß der kardialen Amyloidose genau zu charakterisieren, die zugrunde liegende Amyloidoseform sicher zu identifizieren und anschließend eine gezielte Behandlung zu ermöglichen.

Nur mit Berechtigung zugänglich

Vaxman I, Gertz M (2019) Recent advances in the diagnosis, risk stratification, and management of systemic light-chain Amyloidosis. Acta Haematol 141(2):93–106CrossRefPubMed

Ablasser K, Verheyen N, Glantschnig T, Agnetti G, Rainer PP (2018) Unfolding cardiac Amyloidosis—from Pathophysiology to cure. Curr Med Chem. https://doi.org/10.2174/0929867325666180104153338 CrossRef

Hammarstrom P, Jiang X, Hurshman AR, Powers ET, Kelly JW (2002) Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci U S A 99(Suppl 4):16427–16432CrossRefPubMedPubMedCentral

Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349(6):583–596CrossRefPubMed

Bourgault S, Choi S, Buxbaum JN, Kelly JW, Price JL, Reixach N (2011) Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs. Biochem Biophys Res Commun 410(4):707–713CrossRefPubMedPubMedCentral

Rocken C, Shakespeare A (2002) Pathology, diagnosis and pathogenesis of AA amyloidosis. Virchows Arch 440(2):111–122CrossRefPubMed

Kyle RA, Linos A, Beard CM, Linke RP, Gertz MA, O’Fallon WM, Kurland LT (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79(7):1817–1822CrossRefPubMed

Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Rajkumar SV, Hogan WJ, Leung N, Grogan M, Gertz MA (2012) High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 119(5):1117–1122 (2)CrossRefPubMedPubMedCentral

Cornwell GG III, Murdoch WL, Kyle RA, Westermark P, Pitkanen P (1983) Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 75(4):618–623CrossRefPubMed

10.

Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, Bornstein B, Salas C, Lara-Pezzi E, Alonso-Pulpon L, Garcia-Pavia P (2015) Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36(38):2585–2594CrossRefPubMed

11.

Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, Roger VL, Gertz MA, Dispenzieri A, Zeldenrust SR, Redfield MM (2014) Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. Jacc Heart Fail 2(2):113–122 (Apr)CrossRefPubMedPubMedCentral

12.

Koivuniemi R, Paimela L, Suomalainen R, Tornroth T, Leirisalo-Repo M (2008) Amyloidosis is frequently undetected in patients with rheumatoid arthritis. Amyloid 15(4):262–268CrossRefPubMed

13.

Rapezzi C, Lorenzini M, Longhi S, Milandri A, Gagliardi C, Bartolomei I, Salvi F, Maurer MS (2015) Cardiac amyloidosis: the great pretender. Heart Fail Rev 20(2):117–124CrossRefPubMed

14.

Desport E, Bridoux F, Sirac C, Delbes S, Bender S, Fernandez B, Quellard N, Lacombe C, Goujon JM, Lavergne D, Abraham J, Touchard G, Fermand JP, Jaccard A (2012) Al amyloidosis. Orphanet J Rare Dis 7:54CrossRefPubMedPubMedCentral

15.

Feng D, Edwards WD, Oh JK, Chandrasekaran K, Grogan M, Martinez MW, Syed IS, Hughes DA, Lust JA, Jaffe AS, Gertz MA, Klarich KW (2007) Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 116(21):2420–2426CrossRefPubMed

16.

Tsai SB, Seldin DC, Wu H, O’Hara C, Ruberg FL, Sanchorawala V (2011) Myocardial infarction with “clean coronaries” caused by amyloid light-chain AL amyloidosis: a case report and literature review. Amyloid 18(3):160–164CrossRefPubMed

17.

Dorbala S, Vangala D, Bruyere J Jr., Quarta C, Kruger J, Padera R, Foster C, Hanley M, Di Carli MF, Falk R (2014) Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. Jacc Heart Fail 2(4):358–367CrossRefPubMedPubMedCentral

18.

Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G (2015) Light chain Amyloidosis: patient experience survey from the Amyloidosis research consortium. Adv Ther 32(10):920–928CrossRefPubMedPubMedCentral

19.

Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Colby C, Laumann K, Zeldenrust SR, Leung N, Dingli D, Greipp PR, Lust JA, Russell SJ, Kyle RA, Rajkumar SV, Gertz MA (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol 30(9):989–995CrossRefPubMedPubMedCentral

20.

Rapezzi C, Quarta CC, Riva L, Longhi S, Gallelli I, Lorenzini M, Ciliberti P, Biagini E, Salvi F, Branzi A (2010) Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol 7(7):398–408CrossRefPubMed

21.

Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, Ciliberti P, Pastorelli F, Biagini E, Coccolo F, Cooke RM, Bacchi-Reggiani L, Sangiorgi D, Ferlini A, Cavo M, Zamagni E, Fonte ML, Palladini G, Salinaro F, Musca F, Obici L, Branzi A, Perlini S (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203–1212CrossRefPubMed

22.

Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C (2017) Addressing common questions encountered in the diagnosis and management of cardiac Amyloidosis. Circulation 135(14):1357–1377CrossRefPubMedPubMedCentral

23.

Nativi-Nicolau J, Maurer MS (2018) Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types. Curr Opin Cardiol 33(5):571–579PubMed

24.

Cavalcante JL, Rijal S, Abdelkarim I, Althouse AD, Sharbaugh MS, Fridman Y, Soman P, Forman DE, Schindler JT, Gleason TG, Lee JS, Schelbert EB (2017) Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis. J Cardiovasc Magn Reson 19(1):98CrossRefPubMedPubMedCentral

25.

Castano A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS (2017) Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J 38(38):2879–2887CrossRefPubMedPubMedCentral

26.

Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC (2016) Occult Transthyretin cardiac Amyloid in severe calcific aortic Stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging 9(8). https://doi.org/10.1161/CIRCIMAGING.116.005066 CrossRefPubMedPubMedCentral

27.

Maurer MS, Hanna M, Grogan M, Dispenzieri A, Witteles R, Drachman B, Judge DP, Lenihan DJ, Gottlieb SS, Shah SJ, Steidley DE, Ventura H, Murali S, Silver MA, Jacoby D, Fedson S, Hummel SL, Kristen AV, Damy T, Plante-Bordeneuve V, Coelho T, Mundayat R, Suhr OB, Waddington CM, Rapezzi C (2016) Genotype and phenotype of Transthyretin cardiac Amyloidosis: THAOS (Transthyretin Amyloid outcome survey). J Am Coll Cardiol 68(2):161–172 (Jul)CrossRefPubMedPubMedCentral

28.

Ruberg FL, Maurer MS, Judge DP, Zeldenrust S, Skinner M, Kim AY, Falk RH, Cheung KN, Patel AR, Pano A, Packman J, Grogan DR (2012) Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS). Am Heart J 164(2):222–228CrossRefPubMed

29.

Connors LH, Sam F, Skinner M, Salinaro F, Sun F, Ruberg FL, Berk JL, Seldin DC (2016) Heart failure resulting from Age-related cardiac Amyloid disease associated with wild-type Transthyretin: a prospective, observational cohort study. Circulation 133(3):282–290CrossRefPubMed

30.

Janssen S, van Rijswijk MH, Meijer S, Ruinen L, Van der Hem GK (1986) Systemic amyloidosis: a clinical survey of 144 cases. Neth J Med 29(11):376–385PubMed

31.

Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD, Hawkins PN (2007) Natural history and outcome in systemic AA amyloidosis. N Engl J Med 356(23):2361–2371CrossRefPubMed

32.

Tanaka F, Migita K, Honda S, Fukuda T, Mine M, Nakamura T, Yamasaki S, Ida H, Kawakami A, Origuchi T, Eguchi K (2003) Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol 21(3):343–346PubMed

33.

Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M (2008) Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant 23(3):941–951CrossRefPubMed

34.

Grogan M, Scott CG, Kyle RA, Zeldenrust SR, Gertz MA, Lin G, Klarich KW, Miller WL, Maleszewski JJ, Dispenzieri A (2016) Natural history of wild-type Transthyretin cardiac Amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68(10):1014–1020CrossRefPubMed

35.

Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, Quarta CC, Rezk T, Whelan CJ, Gonzalez-Lopez E, Lane T, Gilbertson JA, Rowczenio D, Petrie A, Hawkins PN (2018) A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 39(30):2799–2806CrossRefPubMed

36.

Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH (2018) Use of serum Transthyretin as a prognostic indicator and predictor of outcome in cardiac Amyloid disease associated with wild-type Transthyretin. Circ Heart Fail 11(2):e4000CrossRefPubMedPubMedCentral

37.

Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169–1180CrossRefPubMed

38.

Sperry BW, Vranian MN, Hachamovitch R, Joshi H, McCarthy M, Ikram A, Hanna M (2016) Are classic predictors of voltage valid in cardiac amyloidosis? A contemporary analysis of electrocardiographic findings. Int J Cardiol 214:477–481CrossRefPubMed

39.

Namdar M, Steffel J, Jetzer S, Schmied C, Hurlimann D, Camici GG, Bayrak F, Ricciardi D, Rao JY, de AC, Chierchia GB, Sarkozy A, Luscher TF, Jenni R, Duru F, Brugada P (2012) Value of electrocardiogram in the differentiation of hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, amyloidosis, and Fabry disease. Am J Cardiol 109(4):587–593CrossRefPubMed

40.

van den Berg MP, Mulder BA, Klaassen SHC, Maass AH, Van Veldhuisen DJ, van der Meer P, Nienhuis HLA, Hazenberg BPC, Rienstra M (2019) Heart failure with preserved ejection fraction, atrial fibrillation, and the role of senile amyloidosis. Eur Heart J 40(16):1287–1293. https://doi.org/10.1093/eurheartj/ehz057 CrossRefPubMedPubMedCentral

41.

Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, Fedorowski A, Furlan R, Kenny RA, Martin A, Probst V, Reed MJ, Rice CP, Sutton R, Ungar A, van Dijk JG (2018) 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 39(21):1883–1948CrossRefPubMed

42.

Navarro JF, Rivera M, Ortuno J (1992) Cardiac tamponade as presentation of systemic amyloidosis. Int J Cardiol 36(1):107–108CrossRefPubMed

43.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 16(3):233–270CrossRefPubMed

44.

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200CrossRef

45.

Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, Marwick TH, Thomas JD (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98(19):1442–1448CrossRefPubMed

46.

Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, Radu C, Guendouz S, Couetil JP, Benhaiem N, Hittinger L, Dubois-Rande JL, Plante-Bordeneuve V, Mohty D, Deux JF, Damy T (2016) Causes and consequences of longitudinal LV dysfunction assessed by 2D strain Echocardiography in cardiac Amyloidosis. Jacc Cardiovasc Imaging 9(2):126–138CrossRefPubMed

47.

Pagourelias ED, Mirea O, Duchenne J, Van CJ, Delforge M, Bogaert J, Kuznetsova T, Voigt JU (2017) Echo parameters for differential diagnosis in cardiac Amyloidosis: a head-to-head comparison of deformation and Nondeformation parameters. Circ Cardiovasc Imaging 10(3):e5588CrossRefPubMed

48.

Senior R, Becher H, Monaghan M, Agati L, Zamorano J, Vanoverschelde JL, Nihoyannopoulos P, Edvardsen T, Lancellotti P (2017) Clinical practice of contrast echocardiography: recommendation by the European Association of Cardiovascular Imaging (EACVI) 2017. Eur Heart J Cardiovasc Imaging 18(11):1205–1205aCrossRefPubMed

49.

Claus P, Omar AMS, Pedrizzetti G, Sengupta PP, Nagel E (2015) Tissue tracking technology for assessing cardiac mechanics: principles, normal values, and clinical applications. Jacc Cardiovasc Imaging 8(12):1444–1460CrossRefPubMed

50.

Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ (2008) Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 10:54CrossRefPubMedPubMedCentral

51.

Syed IS, Glockner JF, Feng D, Araoz PA, Martinez MW, Edwards WD, Gertz MA, Dispenzieri A, Oh JK, Bellavia D, Tajik AJ, Grogan M (2010) Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. Jacc Cardiovasc Imaging 3(2):155–164CrossRefPubMed

52.

Vogelsberg H, Mahrholdt H, Deluigi CC, Yilmaz A, Kispert EM, Greulich S, Klingel K, Kandolf R, Sechtem U (2008) Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51(10):1022–1030 (Mar)CrossRefPubMed

53.

White JA, Kim HW, Shah D, Fine N, Kim KY, Wendell DC, Al-Jaroudi W, Parker M, Patel M, Gwadry-Sridhar F, Judd RM, Kim RJ (2014) CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis. Jacc Cardiovasc Imaging 7(2):143–156CrossRefPubMedPubMedCentral

54.

Boynton SJ, Geske JB, Dispenzieri A, Syed IS, Hanson TJ, Grogan M, Araoz PA (2016) LGE provides incremental prognostic information over serum Biomarkers in AL cardiac Amyloidosis. Jacc Cardiovasc Imaging 9(6):680–686CrossRefPubMed

55.

Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac Amyloidosis. Circulation 132(16):1570–1579CrossRefPubMedPubMedCentral

56.

Puntmann VO, Peker E, Chandrashekhar Y, Nagel E (2016) T1 mapping in characterizing myocardial disease: a comprehensive review. Circ Res 119(2):277–299CrossRefPubMed

57.

Fontana M, Banypersad SM, Treibel TA, Maestrini V, Sado DM, White SK, Pica S, Castelletti S, Piechnik SK, Robson MD, Gilbertson JA, Rowczenio D, Hutt DF, Lachmann HJ, Wechalekar AD, Whelan CJ, Gillmore JD, Hawkins PN, Moon JC (2014) Native T1 mapping in transthyretin amyloidosis. Jacc Cardiovasc Imaging 7(2):157–165CrossRefPubMed

58.

Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, Gebker R, Doltra A, Kelle S, Khan S, Rogers T, Arroyo UE, Cummins C, Carr-White G, Nagel E, Puntmann VO (2015) T1 mapping in discrimination of hypertrophic phenotypes: hypertensive heart disease and hypertrophic Cardiomyopathy: findings from the international T1 Multicenter cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.115.003285 CrossRefPubMed

59.

Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, Whelan CJ, Myerson SG, Robson MD, Hawkins PN, Neubauer S, Moon JC (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. Jacc Cardiovasc Imaging 6(4):488–497CrossRefPubMed

60.

Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, Mascherbauer J, Nezafat R, Salerno M, Schelbert EB, Taylor AJ, Thompson R, Ugander M, van Heeswijk RB, Friedrich MG (2017) Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the society for cardiovascular magnetic resonance (SCMR) endorsed by the European association for cardiovascular imaging (EACVI). J Cardiovasc Magn Reson 19(1):75CrossRefPubMedPubMedCentral

61.

Martinez-Naharro A, Kotecha T, Norrington K, Boldrini M, Rezk T, Quarta C, Treibel TA, Whelan CJ, Knight DS, Kellman P, Ruberg FL, Gillmore JD, Moon JC, Hawkins PN, Fontana M (2018) Native T1 and extracellular volume in Transthyretin Amyloidosis. Jacc Cardiovasc Imaging. https://doi.org/10.1016/j.jcmg.2018.02.006 CrossRefPubMed

62.

Yilmaz A (2019) The “native T1 versus extracellular volume fraction paradox” in cardiac Amyloidosis: answer to the million-dollar question? JACC Cardiovasc Imaging 12(5):820–822. https://doi.org/10.1016/j.jcmg.2018.03.029 CrossRefPubMed

63.

Bokhari S, Castano A, Pozniakoff T, Deslisle S, Latif F, Maurer MS (2013) (99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 6(2):195–201CrossRefPubMedPubMedCentral

64.

Glaudemans AW, van Rheenen RW, van den Berg MP, Noordzij W, Koole M, Blokzijl H, Dierckx RA, Slart RH, Hazenberg BP (2014) Bone scintigraphy with (99m)technetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis. Amyloid 21(1):35–44CrossRefPubMed

65.

Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, Leone O, Farsad M, Ciliberti P, Bacchi-Reggiani L, Fallani F, Branzi A, Rapezzi C (2005) Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc‑3,3‑diphosphono‑1,2‑propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 46(6):1076–1084CrossRefPubMed

66.

Castano A, Haq M, Narotsky DL, Goldsmith J, Weinberg RL, Morgenstern R, Pozniakoff T, Ruberg FL, Miller EJ, Berk JL, Dispenzieri A, Grogan M, Johnson G, Bokhari S, Maurer MS (2016) Multicenter study of planar technetium 99m Pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac Amyloidosis. Jama Cardiol 1(8):880–889CrossRefPubMed

67.

Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, Wechalekar AD, Berk JL, Quarta CC, Grogan M, Lachmann HJ, Bokhari S, Castano A, Dorbala S, Johnson GB, Glaudemans AW, Rezk T, Fontana M, Palladini G, Milani P, Guidalotti PL, Flatman K, Lane T, Vonberg FW, Whelan CJ, Moon JC, Ruberg FL, Miller EJ, Hutt DF, Hazenberg BP, Rapezzi C, Hawkins PN (2016) Nonbiopsy diagnosis of cardiac Transthyretin Amyloidosis. Circulation 133(24):2404–2412 (Jun)CrossRefPubMed

68.

Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, Wechalekar AD, Hawkins PN, Fontana M (2018) Quantitation of (99m)Tc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid 25(3):203–210CrossRefPubMed

69.

Kim YJ, Ha S, Kim YI (2018) Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis. J Nucl Cardiol. https://doi.org/10.1007/s12350-018-1365-x CrossRefPubMedPubMedCentral

70.

Baratto L, Park SY, Hatami N, Gulaka P, Vasanawala S, Yohannan TK, Herfkens R, Witteles R, Iagaru A (2018) (18)F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. Ejnmmi Res 8(1):66CrossRefPubMedPubMedCentral

71.

Dorbala S, Vangala D, Semer J, Strader C, Bruyere JR Jr., Di Carli MF, Moore SC, Falk RH (2014) Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography. Eur J Nucl Med Mol Imaging 41(9):1652–1662CrossRefPubMed

72.

Lee SP, Lee ES, Choi H, Im HJ, Koh Y, Lee MH, Kwon JH, Paeng JC, Kim HK, Cheon GJ, Kim YJ, Kim I, Yoon SS, Seo JW, Sohn DW (2015) 11C-Pittsburgh B PET imaging in cardiac amyloidosis. Jacc Cardiovasc Imaging 8(1):50–59CrossRefPubMed

73.

Lister-James J, Pontecorvo MJ, Clark C, Joshi AD, Mintun MA, Zhang W, Lim N, Zhuang Z, Golding G, Choi SR, Benedum TE, Kennedy P, Hefti F, Carpenter AP, Kung HF, Skovronsky DM (2011) Florbetapir f‑18: a histopathologically validated beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 41(4):300–304CrossRefPubMed

74.

Genovesi D, Vergaro G, Emdin M, Giorgetti A, Marzullo P (2017) PET-CT evaluation of amyloid systemic involvement with [(18)F]-florbetaben in patient with proved cardiac amyloidosis: a case report. J Nucl Cardiol 24(6):2025–2029CrossRefPubMed

75.

Holzmann M, Nicko A, Kuhl U, Noutsias M, Poller W, Hoffmann W, Morguet A, Witzenbichler B, Tschope C, Schultheiss HP, Pauschinger M (2008) Complication rate of right ventricular endomyocardial biopsy via the femoral approach: a retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 118(17):1722–1728CrossRefPubMed

76.

Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, Hill S, Mahrholdt H, Voehringer M, Schieber M, Klingel K, Kandolf R, Bohm M, Sechtem U (2010) Comparative evaluation of left and right ventricular endomyocardial biopsy: differences in complication rate and diagnostic performance. Circulation 122(9):900–909CrossRefPubMed

77.

Khan T, Selvakumar D, Trivedi S, Rao K, Harapoz M, Thiagalingam A, Denniss AR, Varikatt W (2017) The value of endomyocardial biopsy in diagnosis and guiding therapy. Pathology 49(7):750–756CrossRefPubMed

78.

Kristen AV, Brokbals E, Aus dem SF, Bauer R, Hein S, Aurich M, Riffel J, Behrens HM, Kruger S, Schirmacher P, Katus HA, Rocken C (2016) Cardiac Amyloid load: a prognostic and predictive biomarker in patients with light-chain Amyloidosis. J Am Coll Cardiol 68(1):13–24CrossRefPubMed

79.

Mehta P, Chapel DB, Goyal N, Yu DB, Mor-Avi V, Narang A, Addetia K, Sarswat N, Lang RM, Husain AN, Patel AR (2019) A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters. Echocardiography 36(2):285–291CrossRefPubMed

80.

Fine NM, Arruda-Olson AM, Dispenzieri A, Zeldenrust SR, Gertz MA, Kyle RA, Swiecicki PL, Scott CG, Grogan M (2014) Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. Am J Cardiol 113(10):1723–1727CrossRefPubMed

81.

Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354(13):1362–1369CrossRefPubMed

82.

Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD, Pepys MB, Hawkins PN (2002) Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 346(23):1786–1791CrossRefPubMed

83.

Sattianayagam PT, Hahn AF, Whelan CJ, Gibbs SD, Pinney JH, Stangou AJ, Rowczenio D, Pflugfelder PW, Fox Z, Lachmann HJ, Wechalekar AD, Hawkins PN, Gillmore JD (2012) Cardiac phenotype and clinical outcome of familial amyloid polyneuropathy associated with transthyretin alanine 60 variant. Eur Heart J 33(9):1120–1127CrossRefPubMed

84.

Griffiths BE, Hughes P, Dowdle R, Stephens MR (1982) Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 37(9):711–712CrossRefPubMedPubMedCentral

85.

Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schonland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541–4549CrossRefPubMed

86.

Schonland SO, Dreger P (2012) Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 47(7):895–905CrossRefPubMed

87.

Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, Gillmore JD, Palladini G (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28(6):1031–1037CrossRefPubMed

88.

Venner CP, Lane T, Foard D, Rannigan L, Gibbs SD, Pinney JH, Whelan CJ, Lachmann HJ, Gillmore JD, Hawkins PN, Wechalekar AD (2012) Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119(19):4387–4390CrossRefPubMed

89.

Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C (2018) Tafamidis treatment for patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379(11):1007–1016CrossRefPubMed

90.

Barroso FA, Judge DP, Ebede B, Li H, Stewart M, Amass L, Sultan MB (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24(3):194–204CrossRefPubMed

91.

Adams D, Gonzalez-Duarte A, O’Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Plante-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH III, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB (2018) Patisiran, an RNAi therapeutic, for hereditary Transthyretin Amyloidosis. N Engl J Med 379(1):11–21 (Jul)CrossRefPubMed

92.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Plante-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH III, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceicao I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T (2018) Inotersen treatment for patients with hereditary Transthyretin Amyloidosis. N Engl J Med 379(1):22–31 (Jul)CrossRefPubMed

93.

Solomon SD, Adams D, Kristen A, Grogan M, Gonzalez-Duarte A, Maurer MS, Merlini G, Damy T, Slama MS, Brannagan TH III, Dispenzieri A, Berk JL, Shah AM, Garg P, Vaishnaw A, Karsten V, Chen J, Gollob J, Vest J, Suhr O (2019) Effects of Patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary Transthyretin-mediated Amyloidosis. Circulation 139(4):431–443CrossRefPubMed

94.

Aus dem SF, Bauer R, Aurich M, Buss SJ, Steen H, Altland K, Katus HA, Kristen AV (2015) Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther 9:6319–6325CrossRef

95.

Karlstedt E, Jimenez-Zepeda V, Howlett JG, White JA, Fine NM (2019) Clinical experience with the use of Doxycycline and Ursodeoxycholic acid for the treatment of Transthyretin cardiac Amyloidosis. J Card Fail 25(3):147–153CrossRefPubMed

96.

de Real AD, Costa R, Galvan JM, Filigheddu MT, Trujillo D, Cadinanos J (2014) Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol 6:369–377CrossRef

97.

Okamoto S, Wixner J, Obayashi K, Ando Y, Ericzon BG, Friman S, Uchino M, Suhr OB (2009) Liver transplantation for familial amyloidotic polyneuropathy: impact on Swedish patients’ survival. Liver Transpl 15(10):1229–1235CrossRefPubMed

98.

Suhr OB, Larsson M, Ericzon BG, Wilczek HE (2016) Survival after transplantation in patients with mutations other than val30met: extracts from the FAP world transplant registry. Transplantation 100(2):373–381CrossRefPubMedPubMedCentral

99.

Yazaki M, Mitsuhashi S, Tokuda T, Kametani F, Takei YI, Koyama J, Kawamorita A, Kanno H, Ikeda SI (2007) Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients. Am J Transplant 7(1):235–242CrossRefPubMed

100.

Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Poterucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015) Liver transplantation for hereditary Transthyretin Amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99(9):1847–1854CrossRefPubMed

101.

Stangou AJ, Hawkins PN (2004) Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol 17(5):615–620CrossRefPubMed

102.

Koike H, Katsuno M (2019) Ultrastructure in Transthyretin Amyloidosis: from Pathophysiology to therapeutic insights. Biomedicines. https://doi.org/10.3390/biomedicines7010011 CrossRefPubMedPubMedCentral

103.

Palladini G, Malamani G, Co F, Pistorio A, Recusani F, Anesi E, Garini P, Merlini G (2001) Holter monitoring in AL amyloidosis: prognostic implications. Pacing Clin Electrophysiol 24(8 Pt 1):1228–1233CrossRefPubMed

104.

Varr BC, Zarafshar S, Coakley T, Liedtke M, Lafayette RA, Arai S, Schrier SL, Witteles RM (2014) Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm 11(1):158–162CrossRefPubMed

105.

Sayed RH, Rogers D, Khan F, Wechalekar AD, Lachmann HJ, Fontana M, Mahmood S, Sachchithanantham S, Patel K, Hawkins PN, Whelan CJ, Gillmore JD (2015) A study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis. Eur Heart J 36(18):1098–1105 (May)CrossRefPubMed

106.

Kristen AV, Dengler TJ, Hegenbart U, Schonland SO, Goldschmidt H, Sack FU, Voss F, Becker R, Katus HA, Bauer A (2008) Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 5(2):235–240CrossRefPubMed

107.

Lin G, Dispenzieri A, Kyle R, Grogan M, Brady PA (2013) Implantable cardioverter defibrillators in patients with cardiac amyloidosis. J Cardiovasc Electrophysiol 24(7):793–798 (Jul)CrossRefPubMed

108.

Patel KS, Hawkins PN, Whelan CJ, Gillmore JD (2014) Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis. Bmj Case Rep. https://doi.org/10.1136/bcr-2014-206600 CrossRefPubMedPubMedCentral

109.

Lin G, Dispenzieri A, Brady PA (2010) Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death. Eur Heart J 31(12):1538CrossRefPubMed

110.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, Elliott PM, Fitzsimons D, Hatala R, Hindricks G, Kirchhof P, Kjeldsen K, Kuck KH, Hernandez-Madrid A, Nikolaou N, Norekval TM, Spaulding C, Van Veldhuisen DJ (2015) ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European society of cardiology (ESC). Endorsed by: association for European Paediatric and congenital cardiology (AEPC). Eur Heart J 36(41):2793–2867CrossRefPubMed

111.

Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, Kapa S, Kremers MS, Lindsay BD, Stevenson LW (2013) ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American college of cardiology foundation appropriate use criteria task force, heart rhythm society, American heart association, American society of Echocardiography, heart failure society of america, society for cardiovascular Angiography and interventions, society of cardiovascular computed Tomography, and society for cardiovascular magnetic resonance. J Am Coll Cardiol 61(12):1318–1368CrossRefPubMed

112.

Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, Deal BJ, Dickfeld T, Field ME, Fonarow GC, Gillis AM, Granger CB, Hammill SC, Hlatky MA, Joglar JA, Kay GN, Matlock DD, Myerburg RJ, Page RL (2017) AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. J Am Coll Cardiol 72(14):e91–e220CrossRef

113.

Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cleland J, Deharo JC, Delgado V, Elliott PM, Gorenek B, Israel CW, Leclercq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas PE, Zamorano JL, Achenbach S, Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Kirchhof P, Blomstrom-Lundqvist C, Badano LP, Aliyev F, Bansch D, Baumgartner H, Bsata W, Buser P, Charron P, Daubert JC, Dobreanu D, Faerestrand S, Hasdai D, Hoes AW, Le Heuzey JY, Mavrakis H, McDonagh T, Merino JL, Nawar MM, Nielsen JC, Pieske B, Poposka L, Ruschitzka F, Tendera M, Van Gelder IC, Wilson CM (2013) 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 34(29):2281–2329CrossRefPubMed

114.

Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Hogan WJ, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, McGregor CG, Jaffe AS (2004) Prognostication of survival using cardiac troponins and N‑terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 104(6):1881–1887CrossRefPubMed

115.

Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 26(11):2317–2325CrossRefPubMed

Titel: Diagnostik und Therapie der kardialen Amyloidose
Positionspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK)
verfasst von: Univ.-Prof. Dr. med. A. Yilmaz
Univ.-Prof. Dr. med. J. Bauersachs
PD Dr. med. I. Kindermann
Prof. Dr. med. K. Klingel
Prof. Dr. med. F. Knebel
Prof. Dr. med. B. Meder
Dr. med. C. Morbach
Univ.-Prof. Dr. med. E. Nagel
Univ.-Prof. Dr. med. E. Schulze-Bahr
Dr. med. F. aus dem Siepen
Univ.-Prof. Dr. med. N. Frey
Publikationsdatum: 23.08.2019
Verlag: Springer Medizin
Schlagwörter: Szintigrafie
Magnetresonanztomografie
Amyloidose des Herzens
Magnetresonanztomografie
AL-Amyloidose
Amyloidosen
AA-Amyloidose
Erschienen in: Die Kardiologie / Ausgabe 5/2019
Print ISSN: 2731-7129
Elektronische ISSN: 2731-7137
DOI: https://doi.org/10.1007/s12181-019-00344-5

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Diagnostik und Therapie der kardialen Amyloidose

Positionspapier der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK)

Zusammenfassung

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Rezidivierende Phasen von Schwindel und Synkopen – sehen Sie die Ursache im EKG?

CABANA-Studie mit Folgen: Katheterablation bei Vorhofflimmern – das ist der aktuelle Stand

Akute Herzinsuffizienz im Wochenbett – was war die Ursache?

CME: Diagnose und Behandlung ventrikulärer Extrasystolen

Welchen Stellenwert hat die kardiale MRT bei MI﻿NOCA?

Tragbarer Defibrillator: aktuelle Handlungsempfehlungen zum Einsatz

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Welchen Stellenwert hat die kardiale MRT bei MINOCA?